电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant SARS-CoV-2 Nucleocapsid 抗体

This anti-SARS-CoV-2 Nucleocapsid antibody is a Human 单克隆 antibody detecting SARS-CoV-2 Nucleocapsid in ELISA 和 IF. Suitable for SARS Coronavirus-2 (SARS-CoV-2) 和 SARS Coronavirus (SARS-CoV). This Primary Antibody has been cited in 1 publication.
产品编号 ABIN6953102
发货至: 中国

Quick Overview for Recombinant SARS-CoV-2 Nucleocapsid 抗体 (ABIN6953102)

抗原

See all SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) 抗体
SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

抗体类型

Recombinant Antibody

适用

  • 85
  • 7
  • 4
  • 4
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)

宿主

  • 34
  • 30
  • 24
  • 4
  • 1
  • 1
Human

克隆类型

  • 71
  • 16
  • 6
单克隆

标记

  • 71
  • 15
  • 5
  • 1
  • 1
This SARS-CoV-2 Nucleocapsid antibody is un-conjugated

应用范围

  • 83
  • 39
  • 11
  • 10
  • 8
  • 6
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
ELISA, Immunofluorescence (IF)

克隆位点

CR3018 (03-018)
  • 原理

    Anti-Covid-19 & SARS-CoV Nucleoprotein [CR3018 (03-018)], Human IgA1, kappa

    特异性

    This antibody binds the amino acid residues between 11-19 of the N protein of the SARS CoV as well as SARS-CoV-2 (COVID-19) nucleocapsid protein.

    交叉反应

    SARS Coronavirus-2 (SARS-CoV-2)

    产品特性

    Original Species of Ab: Human

    Original Format of Ab: IgG1

    纯化方法

    Affinity Purified using a recombinant lectin column

    免疫原

    The original antibody was generated by cloning the variable regions of the scFvs selected from phage display libraries into separate vectors for IgG1 heavy-chain and light-chain expression. The harvested supernatents were then purified on protein A columns. The original immunogen was the whole irradiated virion.

    亚型

    IgA1 kappa
  • 应用备注

    This antibody is recommended for detection of SARS CoV2 protein N (nucleoprotein). This antibody binds both the nucleocapsid protein of the SARS-CoV and SARS CoV-2 (2019-nCoV). Initial characterization of the antibody for binding to 2019-nCoV was done using ELISA. This antibody shows potential to be used for development of diagnostic assays. Various isotype versions of the antibody namely human IgG1, IgG3, IgM, IgA and the less common IgG2 and IgG4 are available for the investigation of their role in response to SARS CoV2. Competitive ELISA of this antibody with CR3009 suggests that both these antibodies bind different epitopes of the N protein of SARS CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Immunofluorescence staining was used to demonstrate binding of CR3018 to SARS-CoV infected Vero cells. (PMID:15650189)

    说明

    This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    限制

    仅限研究用
  • 状态

    Liquid

    浓度

    1 mg/mL

    缓冲液

    PBS with 0.02 % Proclin 300.

    储存液

    ProClin

    注意事项

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    储存条件

    4 °C,-20 °C

    储存方法

    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • van den Brink, Ter Meulen, Cox, Jongeneelen, Thijsse, Throsby, Marissen, Rood, Bakker, Gelderblom, Martina, Osterhaus, Preiser, Doerr, de Kruif, Goudsmit: "Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus." in: Journal of virology, Vol. 79, Issue 3, pp. 1635-44, (2005) (PubMed).

  • 抗原

    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

    别名

    SARS-CoV-SARS-CoV-2 Nucleocapsid Protein2 N

    物质类

    Viral Protein

    背景

    NP, NC, Protein N, Nucleocapsid protein, SARS-CoV Protein N, SARS-CoV Nucleocapsid protein, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV

    UniProt

    P0DTC9, P59595
You are here:
Chat with us!